ChemoSNiP: Cancer drug response testing

Tailoring cancer treatment through tumor drug response testing

ChemoSNiP is a cutting-edge pharmacogenomic test that analyzes how each patient’s body metabolizes and responds to specific cancer drugs, such as chemotherapy agents. By identifying key genetic variations that influence tumor drug effectiveness and toxicity, ChemoSNiP enables clinicians to make informed, personalized cancer treatment decisions.

The ChemoSNiP test helps determine:

• Which medications are likely to be most effective for a specific patient
• Provides insights on how drugs are metabolized to prevent excessive toxicity
• The best possible drug combinations for safe and effective cancer therapy

With ChemoSNiP from RGCC, clinicians gain powerful insights into how a patient’s unique genetic profile influences drug metabolism, ensuring more precise and effective cancer treatment planning.

How does the  ChemoSNiP test work?

Based on the foundation of precision medicine and liquid biopsy, ChemoSNiP applies the principles of pharmacogenomics (PGx), the study of how genes affect a person’s response to cancer drugs. Pharmacogenomics testing methods can help tailor medications to a person’s genetics to optimize tumor treatments.

After a simple blood draw, our scientists analyze the sample to identify Single-Nucleotide Polymorphisms (SNPs), which are variations in DNA that can influence how the body processes and reacts to medications.

The cancer blood test evaluates:

• Pharmacogenomics (PGx): How genetic variations affect the patient’s biological response to those drugs.

This analysis helps predict whether a patient will have a positive, negative, or no response to specific chemotherapeutic agents.

When combined with data from chemosensitivity testing, ChemoSNiP helps narrow down treatment options to the most effective and least toxic therapeutic agents, enhancing both treatment precision and patient safety.

Having this information before starting therapy empowers clinicians to confidently make data-driven decisions and gives patients the best chance for successful outcomes.

Who should get a ChemoSNiP test?

The ChemoSNiP test is recommended for:

• Cancer patients preparing to begin chemotherapy or targeted drug treatment.
• Patients who have experienced limited success or high toxicity with previous therapies.
• Clinicians seeking to optimize treatment plans based on pharmacogenomic insights.

By tailoring therapy to each patient’s unique genetic makeup, ChemoSNiP helps advance the principles of precision oncology, improving treatment effectiveness and minimizing side effects.